Cancer

Title Average Ratingsort ascending
Role of everolimus in the treatment of renal cell carcinoma. 50.00%
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell.. 50.00%
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. 50.00%
Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. 50.00%
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal 50.00%
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom 50.00%
An RF hyperthermia electrode which generates no edge effect. 50.00%
Cancer Prevention 50.00%
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosp 50.00%
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit 50.00%
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. 50.00%
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer 50.00%
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? 50.00%
Some pharmacological properties of prolonged administration of Ukrain in rodents 50.00%
Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1 50.00%
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... 50.00%
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. 50.00%
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. 50.00%
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line 50.00%
Tumoral angiogenesis: review of the literature. 50.00%
Effect of alkaloid sanguinarine and a pharmaceutical preparation ukrain on modulation of vesicular membrane fusion and actin.... 50.00%
A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study 50.00%
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryother 50.00%
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera 50.00%
Novel anti-angiogenic therapies for malignant gliomas. 50.00%
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. 50.00%
Melatonin 45.00%
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr 45.00%
Ukrain: acute toxicity after intravenous, intramuscular and oral administration in rats 40.00%
Pancreatic cancer stem cells - insights and perspectives. 40.00%
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. 40.00%
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. 40.00%
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. 40.00%
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. 40.00%
Serum cytokines in pancreatic cancer: Correlation with outcome 40.00%
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. 40.00%
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. 40.00%
Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. 40.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... 40.00%
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. 40.00%
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. 40.00%
Long term outcomes following surgical resection of myxopapillary ependymomas. 40.00%
Mistletoe in conventional oncological practice: exemplary cases. 40.00%
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non..... 40.00%
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco 40.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat 40.00%
In vitro and in vivo antiproliferative activity of laherradurin and cherimolin-2 of Annona diversifolia Saff. 40.00%
Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations. 40.00%
Ependymoma. 40.00%
Enhancement of macrophage tumouricidal activity by the alkaloid derivative 40.00%
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report) 40.00%
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. 40.00%
Bioavailability of sorafenib tablets administered as a liquid suspension. 30.00%
A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followe 30.00%
Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. 30.00%
The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy 30.00%
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. 30.00%
Effect of Ukrain on the efficacy of anti-epileptic drugs against maximal electroshock-induced seizures in mice. 30.00%
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... 30.00%
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the 30.00%
Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of m 30.00%
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. 30.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... 30.00%
A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillar... 30.00%
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz 25.00%
Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain. 20.00%
The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs 20.00%
Mistletoe as a treatment for cancer. Has no proved benefit, and can cause harm 20.00%
Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report) 20.00%
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. 20.00%
Removed because of suspicion of scientific fraud: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. 10.00%
Herbal Based Cancer Therapies 10.00%
The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing 0.00%
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer........ 0.00%
Aging: gene silencing or gene activation? 0.00%
Six-week treatment with Ukrain in rabbits. Part III: Serum levels of thyroid hormones 0.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. 0.00%
Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. 0.00%
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retar 0.00%
Teratological evaluation of Ukrain in hamsters and rats 0.00%
Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort s 0.00%
Breast Cancer 0.00%
Evaluation of mutagenic, genotoxic and transforming properties of Ukrain 0.00%
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.... 0.00%
Breast Cancer Treatment 0.00%
WITHDRAWN: Multi-agent chemotherapy for early breast cancer. 0.00%
Homeopatic therapy in Cancer Treatment 0.00%
Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. 0.00%
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhib 0.00%
Gemcitabine 0.00%
Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. 0.00%
Preliminary pharmacokinetic studies of Ukrain in rats 0.00%
PSMA - Lutetium Treatment 0.00%
High Dose Intravenous Vitamin C 0.00%
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) stud 0.00%
Dentists, dental nurses, and brain tumours 0.00%
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. 0.00%
Effect of Ukrain on human liver alcohol dehydrogenase activity in vitro. 0.00%
Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carci 0.00%
IV Artesunate 0.00%

Pages